Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Blood Cancer Journal|January 15, 2024
Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation riskAshwin Kishtagari, M A Wasay Khan, Yajing Li, et al.
Immunohorizons|December 22, 2022
Acly Deficiency Enhances Myelopoiesis through Acetyl Coenzyme A and Metabolic-Epigenetic Cross-TalkDalton L Greenwood, Haley E Ramsey, Phuong T T Nguyen, et al.
Journal of Hematology & Oncology|January 17, 2025
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trialJorge E Cortes, Gail J Roboz, Maria R Baer, et al.
Blood Advances|March 20, 2024
Multiomic profiling of human clonal hematopoiesis reveals genotype and cell-specific inflammatory pathway activationJ Brett Heimlich, Pawan Bhat, Alyssa C Parker, et al.
Targeted Oncology|July 29, 2021
Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced DifferentiationHaley E Ramsey, Kristy Stengel, James C Pino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2025
Clonal Hematopoiesis of Indeterminate Potential Influences Breast Cancer Outcomes in a Genotype-Specific MannerSarah C Reed, Chad R Potts, Leo Y Luo, et al.
Blood Advances|April 12, 2024
Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepositoryMorgan L Shannon, J Brett Heimlich, Sydney Olson, et al.
JCI Insight|December 21, 2018
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagementDouglas B Johnson, Mellissa J Nixon, Yu Wang, et al.
Nature|November 17, 2022
T cells specific for α-myosin drive immunotherapy-related myocarditisMargaret L Axelrod, Wouter C Meijers, Elles M Screever, et al.
The Lancet. Haematology|November 12, 2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialJustin M Watts, Maria R Baer, Jay Yang, et al.
Pageof 15